Skip to main content
Clinical Trials/NCT05316363
NCT05316363
Completed
N/A

Efficacy and Safety of Osteopathic Manipulative Treatment on Asthmatics

Western University of Health Sciences0 sites32 target enrollmentDecember 11, 2012
ConditionsAsthma

Overview

Phase
N/A
Intervention
Not specified
Conditions
Asthma
Sponsor
Western University of Health Sciences
Enrollment
32
Primary Endpoint
Asthma Control Test (ACT) Score
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is a pilot study in which the objective is to determine the feasibility of a randomized clinical trial investigating the safety and efficacy of OMT as an adjunctive treatment for patients with mild to moderate asthma compared to the same patient population without the use of OMT. OMT may be able to correct anatomical dysfunctions that contribute to increased symptoms in asthmatic patients. OMT's effect on asthma will be demonstrated by symptomatology reporting, frequency of medication use, and pulmonary function tests.

Detailed Description

Asthma is a leading cause of activity limitation and healthcare burden in the United States of America. The asthmatic population is in need of treatments that target reducing asthma symptoms, reduce the need for medication, and improve lung functionality. As of today, there are not many studies investigating the efficacy and safety of osteopathic manipulative treatment (OMT) on asthmatic patients. This is a pilot study in which the objective is to determine the feasibility of a randomized clinical trial investigating the safety and efficacy of OMT as an adjunctive treatment for patients with mild to moderate asthma compared to the same patient population without the use of OMT. Subjects will be randomized into either a control group or an intervention group where OMT will be used in conjunction with standard asthmatic treatment. Subjective and objective measurements will be taken including the Asthma Control Test (ACT) questionnaire, peak flow, spirometry, pulse oximetry, and chest/diaphragmatic excursion measurements. Measurements will be compared from baseline, before the first treatment and at the follow-up visit after the final treatment.

Registry
clinicaltrials.gov
Start Date
December 11, 2012
End Date
January 8, 2015
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jesus Sanchez

Assistant Dean of Academic Affairs, Professor of NMM/OMM & Family Medicine

Western University of Health Sciences

Eligibility Criteria

Inclusion Criteria

  • Clinically diagnosed with mild to moderate asthma (Episodic symptoms included were airflow obstruction or airway hyper-responsiveness, and airflow obstruction that was at least partially reversible (based upon an increase in FEV1 or greater than or equal to 12% from baseline or by an increase of at least 10% of predicted FEV1 after inhalation of a short-acting bronchodilator)

Exclusion Criteria

  • pneumonia
  • COPD as a primary diagnosis
  • pulmonary fibrosis
  • smoking history
  • inability to perform pulmonary function tests
  • history of recent myocardial infarction or heart disease
  • unable to respond to the questionnaire
  • unable to provide informed consent
  • using muscle relaxants
  • Any contraindications to OMT such as: known bone metastases, severe osteoporosis, osteomyelitis, or fracture

Outcomes

Primary Outcomes

Asthma Control Test (ACT) Score

Time Frame: Between baseline and 5 weeks

Determine the efficacy of adjunctive OMT treatment when compared to standard care in the reduction of symptomatology of dyspnea, wheezing and bronchoconstriction and decrease medication use as measured by the Expert Panel Report 3 and Global Initiative for Asthma Monitoring Asthma Control Test (ACT) questionnaire which is scored on a range from 5 to 25 with higher scores indicating better control of asthma symptoms.

Secondary Outcomes

  • Pulse Oximetry (Blood O2 Saturation Levels)(Between baseline and 5 weeks)
  • Morphological Measurements of Chest and Diaphragm Excursion(Between baseline and 5 weeks)
  • Pulse Oximetry (Pulse Rate)(Between baseline and 5 weeks)
  • Spirometry Readings: Forced Expiratory Volume in One Second (FEV1)(Between baseline and 5 weeks)

Similar Trials